Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Anticancer Research Année : 2010

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Résumé

For this patient population, low dose metronomic cyclophosphamide prednisolone might be a viable alternative. Its convenient oral administration, low cost, and lack of toxicity justify further studies alone, or in combination with other agents in HRPC patients.

Domaines

Immunologie
Fichier non déposé

Dates et versions

inserm-00555027 , version 1 (12-01-2011)

Identifiants

  • HAL Id : inserm-00555027 , version 1
  • PUBMED : 21036758

Citer

Sylvain Ladoire, Jean-Christophe Eymard, Sylvie Zanetta, Grégoire Mignot, Etienne Martin, et al.. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.. Anticancer Research, 2010, 30 (10), pp.4317-23. ⟨inserm-00555027⟩
128 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More